UCB SA has confirmed that revenue for 2011 should be in the range of €3 to €3.1 billion, or below the company’s 2010 revenue of €3.2 billion, as it makes the transition from a legacy portfolio to one anchored in new patent-protected products. ---Subscribe to MedNous to access this article--- Company News
